Showing 1 - 9 of 9
Persistent link: https://www.econbiz.de/10012114958
IP provisions in FTAs may have implications on a wide range of public policy areas. A vast academic literature has addressed the "flexibilities" available under the TRIPS Agreement and the negative impact of FTAs in relation to access to medicines. For example, the Special Rapporteur on the...
Persistent link: https://www.econbiz.de/10011637209
The unequal global distribution of vaccines against the deadly COVID-19 virus has cast a spotlight on the lack of access to vaccines on the African continent, and the vulnerability that such a lack places on both the economies of African nations and the health of their people. Various...
Persistent link: https://www.econbiz.de/10014284597
Most free trade agreements signed by the United States, the European Union and the members of the European Free Trade Association (EFTA) in the last 15 years contain chapters on intellectual property rights with provisions applicable to pharmaceuticals. Such provisions considerably expand the...
Persistent link: https://www.econbiz.de/10011342184
Persistent link: https://www.econbiz.de/10010457416
While increasing support from WTO members for a proposed waiver from certain obligations under the TRIPS Agreement with regard to health products required for responding to COVID-19 has made a decision on the TRIPS waiver imminent, the waiver will have to be implemented domestically by WTO...
Persistent link: https://www.econbiz.de/10012696525
Persistent link: https://www.econbiz.de/10012490829
Most free trade agreements (FTAs) signed by the United States, the European Union and the members of the European Free Trade Association (EFTA) in the last 15 years contain chapters on intellectual property rights with provisions applicable to pharmaceuticals. Such provisions considerably expand...
Persistent link: https://www.econbiz.de/10012490836
IP provisions in FTAs may have implications on a wide range of public policy areas. A vast academic literature has addressed the "flexibilities" available under the TRIPS Agreement and the negative impact of FTAs in relation to access to medicines. For example, the Special Rapporteur on the...
Persistent link: https://www.econbiz.de/10012490848